Both Croda’s US sites receive GMP certification for excipients

Published: 6-Apr-2017
Manufacturing Ingredients Regulatory

The scope covers alkyloxylates, esters, super refined oils and polyethylene glycol (PEG)

Both Croda manufacturing sites in the USA have been awarded an EXCiPACT Certificate from SGS, one of EXCIPACT’s internationally-recognised Certification Bodies.

The certificates demonstrates that the Croda sites in Mill Hall, Pennsylvania and in New Castle, Delaware manufacture pharmaceutical excipients according to the EXCiPACT Good Manufacturing Practice (GMP) Certification Standard.

The scope covers the manufacturing of alkyloxylates, esters, super refined oils and polyethylene glycol (PEG) at Mill Hall, as well as alkyloxylates and esters at New Castle.

  • Companies:
  • Croda Beauty
See more

You may also like

Distribution

CPHI Annual Report: Building a more resilient supply chain for excipients

Read more
Ahead of CPHI, which is back in Frankfurt this year from 1–3 November with visitor numbers expected to meet or exceed prepandemic levels, Iain Moore, Head of Global Quality Assurance, Croda International, and EXCiPACT co-ordinator, discusses supply chain disruptions in the excipient industry and the positive impact of it moving forward

Trending Articles

  1. TekniPlex Healthcare to showcase expanded capacity and sustainability solutions at Pharmapack Company highlights EU-based advancements in injection blow molding, multilayer blown films, and sustainable blister packaging
  2. Causes and solutions for dark spots in tablet manufacturing Natoli Engineering examines the causes and solutions for dark spots that can halt production
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Rousselot Biomedical launches EU MDR compliant gelatin range From May 2024, all devices placed on the European market must conform with the EU Medical Device Regulation (MDR)

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Distribution

CPHI Annual Report: Building a more resilient supply chain for excipients

Ahead of CPHI, which is back in Frankfurt this year from 1–3 November with visitor numbers expected to meet or exceed prepandemic levels, Iain Moore, Head of Global Quality Assurance, Croda International, and EXCiPACT co-ordinator, discusses supply chain disruptions in the excipient industry and the positive impact of it moving forward
Manufacturing

Developments in global pharmaceutical excipients in the next 3–5 years: part II

Key themes that will shape the excipient landscape in the near future will include regulations, innovation, economics and sustainability, says Dr Iain Moore, Head of Global Quality Assurance, Croda International, in this year’s <i>CPhI Annual Report</i>
Manufacturing

Developments in global pharmaceutical excipients in the next 3–5 years: part I

Key themes that will shape the excipient landscape in the near future will include regulations, innovation, economics and sustainability, says Dr Iain Moore, Head of Global Quality Assurance, Croda International, in this year’s <i>CPhI Annual Report</i>
Manufacturing

Croda Europe gains EXCiPACT certification at sites at Rawcliffe Bridge and Thorne in the UK

The first UK site to receive certification
You need to be a subscriber to read this article.
Click here to find out more.
Media

Good growth for ingredients, but costs could rise

In the fast growing API and excipient markets, solubility, taste-masking and functionality are the focus. Susan Birks looks at current trends and issues on the horizon
Ingredients

Croda announces record H1 results

Pre-tax profit jumps 30%; Q2 results remain strong
Manufacturing

Croda’s turnover passes the £1bn mark for the first time

Chemical company reports record profits for 2010
Subscribe now